Publications by authors named "Huth Felix"

Claim this Profile
G
Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework.
Filip Cuyckens, Wenying Li, Adam M Auclair, Kenneth C Cassidy, Cathy Cantalloube, Felix Huth

Clin Pharmacol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan

Clin Pharmacol Drug Dev· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations.
Jesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, Rongrong Rosa Jiang, Carol Kuo, Felix Huth

Nucleic Acids Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib.
Ioannis Loisios-Konstantinidis, Felix Huth, Matthias Hoch, Heidi J Einolf

Pharmaceutics· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4/5 inhibition potential of drugs.
Badée Justine, Gu Helen, Huth Felix, Poller Birk, Schiller Hilmar

Drug Metab Dispos· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms.
Vlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, Felix Huth, Heiko S Schadt

Arch Toxicol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.
Ulrike Glaenzel, Felix Huth, Fabian Eggimann, Melissa Hackling, Luc Alexis Leuthold

Drug Metab Dispos· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology of Asciminib: A Review.
Matthias Hoch, Felix Huth, Paul William Manley, Ioannis Loisios-Konstantinidis, Francois Pierre Combes

Clin Pharmacokinet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC).
Vlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, Felix Huth, Zsuzsanna Gáborik

Arch Toxicol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives.
Felix Huth, Ulrike Glaenzel, Anton Drollmann, Wendy Weis, Julia Zack

Clin Transl Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving In Vitro-In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules.
Markus Trunzer, Joana Teigão, Felix Huth, Birk Poller, Sandrine Desrayaud

Drug Metab Dispos· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth

Clin Pharmacokinet· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
Ryota Kikuchi, Paresh P Chothe, Xiaoyan Chu, Felix Huth, Kazuya Ishida

Clin Pharmacol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell Proteome.
Matthew D Harwood, Katharina Zettl, Manuel Weinheimer, Venkatesh Pilla-Reddy, Hong Shen, Felix Huth

Mol Pharm· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes.
Vlasia Kastrinou Lampou, Birk Poller, Felix Huth, Audrey Fischer, Gerd A Kullak-Ublick

Toxicol In Vitro· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time matters - cellular disposition kinetics help rationalizing cellular potency disconnects.
Birk Poller, Sophie Werner, Norbert Domange, Lina Mettler, Richard R Stein, Felix Huth

Xenobiotica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Matthias Hoch, Felix Huth, Masahiko Sato, Tirtha Sengupta, Michelle Quinlan

Clin Transl Sci· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Hilmar Schiller, Felix Huth, Carole Schuhler, Anton Drollmann, Martin Kaul

Eur J Pharm Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Paul W Manley, Felix Huth, Saliha Moussaoui, Joseph Schoepfer

Bioorg Med Chem Lett· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Matthias Hoch, Julia Zack, Michelle Quinlan, Felix Huth, Sofia Forte

Clin Pharmacol Drug Dev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.
Felix Huth, Hilmar Schiller, Yi Jin, Birk Poller, Carole Schuhler

Clin Transl Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space.
Felix Huth, Norbert Domange, Birk Poller, Arpine Vapurcuyan, Alexandre Durrwell

J Pharm Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Tanay S Samant, Felix Huth, Kenichi Umehara, Hilmar Schiller, Shyeilla V Dhuria

Clin Pharmacol Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Kunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M Posada, Manthena Varma, Felix Huth

Clin Pharmacol Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Anne Gardin, Kasra Shakeri-Nejad, Andrea Feller, Felix Huth, Srikanth Neelakantham

Eur J Clin Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis